Type IV hypersensitivity disease
MONDO:0002459A disease that has its basis in the disruption of type IV hypersensitivity.
Also known as: DTH, delayed hypersensitivity reaction, delayed-type hypersensitivity, delayed-type hypersensitivity response, disorder of type IV hypersensitivity, type 4 hypersensitivity reaction, type IV hypersensitivity, type IV hypersensitivity reaction
20 clinical trials for this condition and its sub-types, 0 tagged with Type IV hypersensitivity disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Type IV hypersensitivity disease
-
Autoimmune lymphoproliferative syndrome 11 trials · 12 incl. sub-types
9 sub-types
- Autoimmune lymphoproliferative syndrome type 4 3 trials
- FAS-related autoimmune lymphoproliferative syndrome 2 trials
- Autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency 1 trial
- Castleman-Kojima disease 0 trials
- Autoimmune lymphoproliferative syndrome type 1 0 trials
- Autoimmune lymphoproliferative syndrome type 2A 0 trials
- Autoimmune lymphoproliferative syndrome type 2B 0 trials
- Autoimmune lymphoproliferative syndrome, type III caused by mutation in PRKCD 0 trials
- Type 3 autoimmune lymphoproliferative syndrome 0 trials
-
Cryoglobulinemia 3 trials
1 sub-type
- Cryofibrinogenemia 0 trials Sub-types →
-
Serum sickness 3 trials
Most studied deeper sub-types
-
Could a stem cell transplant cure immune diseases?
Cure Recruiting nowThis study tests whether a stem cell transplant can cure people with serious immune system disorders. Participants, aged 4 to 69, receive healthy donor stem cells to rebuild their immune system. The goal is to see if the transplant can permanently fix the immune defect and elimin…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Cure
Last updated Aug 21, 2026 00:00 UTC
-
Can a donor stem cell transplant fix broken immune systems?
Disease control Recruiting nowThis study tests whether a stem cell transplant from a healthy donor can help people with severe primary immunodeficiencies. Participants aged 4 to 75 receive chemotherapy before the transplant to prepare their body. The goal is to see if the procedure is safe and can improve imm…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New pill could shrink spleen and lymph nodes in rare ALPS disease
Disease control Recruiting nowThis study tests a drug called soquelitinib in 15 people aged 16 and older with autoimmune lymphoproliferative syndrome (ALPS). The goal is to see if the drug can shrink an enlarged spleen or lymph nodes and improve low blood cell counts. Participants take the pill twice daily fo…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New drug combo aims to tame inflammation before stem cell transplant
Disease control Recruiting nowThis phase 2 study tests whether giving emapalumab or a combination of fludarabine and dexamethasone before a stem cell transplant can reduce inflammation and help the donated cells take hold better. The trial involves 39 people with primary immune regulatory disorders or autoinf…
Phase 2 • Sponsor: Joseph Oved • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Milder chemo before stem cell transplant shows promise for rare blood disorders
Disease control Recruiting nowThis study tracks 50 children and adults with non-malignant disorders like immune deficiencies and anemias who receive a stem cell transplant after a reduced-intensity chemotherapy regimen. The goal is to see if this approach improves survival and reduces severe graft-versus-host…
Sponsor: Paul Szabolcs • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Milder transplant method aims to help young patients with rare blood diseases
Disease control Recruiting nowThis study is testing a less intense chemotherapy and radiation regimen before a stem cell transplant for children and young adults up to age 55 with non-cancerous blood disorders like immune deficiencies, anemias, and metabolic diseases. The goal is to see if this gentler prepar…
Phase 2 • Sponsor: Paul Szabolcs • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Nasal spray vs. needle: new study tests easier allergy rescue
Symptom relief Recruiting nowThis study looks at the safety of a nasal spray called neffy compared to a standard epinephrine shot for treating allergic reactions. It involves 600 people aged 4 and older who have an allergic reaction during a food challenge or allergy shot session. The goal is to see if the s…
Phase 4 • Sponsor: ARS Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Banking blood and bone marrow to decode plasma cell disorders
Knowledge-focused Recruiting nowResearchers at Peking University First Hospital are building a prospective cohort of 2,000 people with plasma cell disorders, including multiple myeloma, amyloidosis, and related conditions. Participants give blood, bone marrow, and urine samples before and after treatment, and t…
Sponsor: Peking University First Hospital • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists track rare immune disease to unlock its secrets
Knowledge-focused Recruiting nowThis study follows people with autoimmune lymphoproliferative syndrome (ALPS) and their relatives over many years. Researchers will collect blood and tissue samples, track symptoms, and study genetics to better understand why the immune system attacks the body. The goal is to lea…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
30 volunteers to reveal how long vaccine antibodies last against two viruses
Knowledge-focused Recruiting nowThis study will follow 30 adults who have received vaccines or antibody treatments for COVID-19 or monkeypox. Researchers will take blood and optional nasal swabs over time to measure how well the body's antibodies neutralize these viruses. The goal is to better understand how lo…
Sponsor: Centre Hospitalier Régional d'Orléans • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
New registry aims to unlock secrets of rare blood disorders
Knowledge-focused Recruiting nowThis study creates a registry for adults with plasma cell disorders, such as multiple myeloma and amyloidosis. Researchers will collect health information and optional blood samples to better understand these conditions. The goal is to gather data that could support future resear…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC